The Scottish Medicines Consortium (SMC), has published advice accepting five new medicines for use by NHSScotland.
The accepted treatments are:
- Teduglutide (Revestive), for the treatment of paediatric onset short bowel syndrome in children aged 1 – 17 years. Teduglutide can reduce the level of parenteral nutrition that is required, enabling patients and their carers to experience an improved quality of life.
- Sofosbuvir-velpatasvir-voxilaprevir (Vosevi) and sofosbuvir-velpatasvir (Epclusa) for the treatment of hepatitis C.
- Sarilumab (Kevzara) was accepted for the treatment of rheumatoid arthritis, and provides another treatment option for adult patients with severe disease who have not responded to or are intolerant of standard therapies.
- Finally, dimethyl fumarate (Skilarence) was accepted for use for the treatment of plaque psoriasis, an inflammatory skin condition disease that causes thickened, red and inflamed areas of skin with scaly patches.
SMC Chairman Dr Alan MacDonald said: “The committee is pleased to be able to accept these five medicines.
“Teduglutide has the potential to improve the quality of life for those who suffer from short bowel syndrome from a young age.
“The two medicines we accepted for hepatitis C will help open up treatment to more patients, including those who have not responded to previous treatments, further helping to meet the Scottish Government’s aim of eradicating this condition.
“Sarilumab provides an alternative for patients who have failed to respond to conventional treatments for rheumatoid arthritis. Dimethyl fumarate (Skilarence) offers another treatment option for use in plaque psoriasis.”